Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103


Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study.

Schwarzer R, Kivaranovic D, Paternostro R, Mandorfer M, Reiberger T, Trauner M, Peck-Radosavljevic M, Ferlitsch A.

Aliment Pharmacol Ther. 2018 Feb 28. doi: 10.1111/apt.14576. [Epub ahead of print]


Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding.

Pfisterer N, Dexheimer C, Fuchs EM, Bucsics T, Schwabl P, Mandorfer M, Gessl I, Sandrieser L, Baumann L, Riedl F, Scheiner B, Pachofszky T, Dolak W, Schrutka-Kölbl C, Ferlitsch A, Schöniger-Hekele M, Peck-Radosavljevic M, Trauner M, Madl C, Reiberger T.

Aliment Pharmacol Ther. 2018 Apr;47(7):966-979. doi: 10.1111/apt.14485. Epub 2018 Feb 1.


Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.

Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, Ay C, Quehenberger P, Fritzer-Szekeres M, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferlitsch A; Vienna Hepatic Hemodynamic Lab.

Aliment Pharmacol Ther. 2018 Apr;47(7):980-988. doi: 10.1111/apt.14522. Epub 2018 Jan 29.


Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension.

Paternostro R, Heinisch BB, Reiberger T, Mandorfer M, Schwarzer R, Seeland B, Trauner M, Peck-Radosavljevic M, Ferlitsch A.

Liver Int. 2018 Jan 24. doi: 10.1111/liv.13704. [Epub ahead of print]


Editorial: getting bullish about portal hypertension-chronic treatment with oral taurine? Author's reply.

Ferlitsch A.

Aliment Pharmacol Ther. 2018 Feb;47(4):534-535. doi: 10.1111/apt.14477. No abstract available.


Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience.

Bucsics T, Schoder M, Diermayr M, Feldner-Busztin M, Goeschl N, Bauer D, Schwabl P, Mandorfer M, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Karner J, Karnel F, Reiberger T.

PLoS One. 2018 Jan 9;13(1):e0189414. doi: 10.1371/journal.pone.0189414. eCollection 2018.


Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection.

Starlinger P, Pereyra D, Haegele S, Braeuer P, Oehlberger L, Primavesi F, Kohler A, Offensperger F, Reiberger T, Ferlitsch A, Messner B, Beldi G, Staettner S, Brostjan C, Gruenberger T.

Hepatology. 2017 Nov 15. doi: 10.1002/hep.29651. [Epub ahead of print]


Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension.

Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, Reiberger T, Ferlitsch M, Gerner C, Trauner M, Peck-Radosavljevic M, Ferlitsch A.

Aliment Pharmacol Ther. 2018 Jan;47(1):86-94. doi: 10.1111/apt.14377. Epub 2017 Nov 3.


ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.

Bucsics T, Hoffman S, Grünberger J, Schoder M, Matzek W, Stadlmann A, Mandorfer M, Schwabl P, Ferlitsch A, Peck-Radosavljevic M, Trauner M, Karner J, Karnel F, Reiberger T.

Liver Int. 2017 Nov 1. doi: 10.1111/liv.13615. [Epub ahead of print]


Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).

Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P.

Wien Klin Wochenschr. 2017 Nov;129(Suppl 3):135-158. doi: 10.1007/s00508-017-1262-3. Epub 2017 Oct 23.


Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice.

Bucsics T, Schoder M, Goeschl N, Schwabl P, Mandorfer M, Diermayr M, Feldner M, Riedl F, Bauer D, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Karner J, Karnel F, Reiberger T.

Dig Liver Dis. 2017 Dec;49(12):1360-1367. doi: 10.1016/j.dld.2017.08.002. Epub 2017 Aug 8.


Effects of Portal Hypertension on Gadoxetic Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications.

Asenbaum U, Ba-Ssalamah A, Mandorfer M, Nolz R, Furtner J, Reiberger T, Ferlitsch A, Kaczirek K, Trauner M, Peck-Radosavljevic M, Wibmer AG.

Invest Radiol. 2017 Aug;52(8):462-469. doi: 10.1097/RLI.0000000000000366.


Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.

Scheiner B, Parada-Rodriguez D, Bucsics T, Schwabl P, Mandorfer M, Pfisterer N, Riedl F, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T.

Scand J Gastroenterol. 2017 Sep;52(9):1008-1015. doi: 10.1080/00365521.2017.1329456. Epub 2017 May 22.


Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.

Schwabl P, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M, Bucsics T, Hayden H, Grabmeier-Pfistershammer K, Ferlitsch A, Oberhuber G, Trauner M, Peck-Radosavljevic M, Reiberger T.

Aliment Pharmacol Ther. 2017 Jan;45(1):139-149. doi: 10.1111/apt.13844. Epub 2016 Nov 7.


Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis.

Paternostro R, Wagner D, Reiberger T, Mandorfer M, Schwarzer R, Ferlitsch M, Trauner M, Peck-Radosavljevic M, Ferlitsch A.

Wien Klin Wochenschr. 2017 Jan;129(1-2):8-15. doi: 10.1007/s00508-016-1127-1. Epub 2016 Nov 25.


Endoscopic versus surgical management of biliary complications - Outcome analysis after 1188 orthotopic liver transplantations.

Györi GP, Schwarzer R, Püspök A, Schöfl R, Silberhumer GR, Langer FB, Trauner M, Peck-Radosavljevic M, Berlakovich GA, Ferlitsch A.

Dig Liver Dis. 2016 Nov;48(11):1323-1329. doi: 10.1016/j.dld.2016.05.016. Epub 2016 May 26.


Risk factors cannot explain the higher prevalence rates of precancerous colorectal lesions in men.

Waldmann E, Heinze G, Ferlitsch A, GessI I, Sallinger D, Jeschek P, Britto-Arias M, Salzl P, Fasching E, Jilma B, Kundi M, Trauner M, Ferlitsch M.

Br J Cancer. 2016 Nov 22;115(11):1421-1429. doi: 10.1038/bjc.2016.324. Epub 2016 Oct 20.


von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy.

Rutter K, Etschmaier A, Ferlitsch M, Maieron A, Hametner S, Horvatits T, Paternostro R, Salzl P, Reiberger T, Peck-Radosavljevic M, Quehenberger P, Hofer H, Trauner M, Ferenci P, Ferlitsch A.

Dig Liver Dis. 2016 Oct;48(10):1194-9. doi: 10.1016/j.dld.2016.06.033. Epub 2016 Jul 19.


Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis.

Horvatits T, Drolz A, Roedl K, Rutter K, Ferlitsch A, Fauler G, Trauner M, Fuhrmann V.

Liver Int. 2017 Feb;37(2):224-231. doi: 10.1111/liv.13201. Epub 2016 Aug 4.


Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.

Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, Chromy D, Stättermayer AF, Reiberger T, Beinhardt S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-Radosavljevic M.

J Hepatol. 2016 Oct;65(4):692-699. doi: 10.1016/j.jhep.2016.05.027. Epub 2016 May 27.


Supplemental Content

Loading ...
Support Center